GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Impedimed Ltd (ASX:IPD) » Definitions » Gross-Profit-to-Asset %

Impedimed (ASX:IPD) Gross-Profit-to-Asset % : 17.69% (As of Jun. 2024)


View and export this data going back to 2007. Start your Free Trial

What is Impedimed Gross-Profit-to-Asset %?

Gross-Profit-to-Asset % is calculated as Gross Profit divided by its average Total Assets over a certain period of time. Impedimed's annualized Gross Profit for the quarter that ended in Jun. 2024 was A$9.34 Mil. Impedimed's average Total Assets over the quarter that ended in Jun. 2024 was A$52.79 Mil. Therefore, Impedimed's annualized Gross-Profit-to-Asset % for the quarter that ended in Jun. 2024 was 17.69%.


Impedimed Gross-Profit-to-Asset % Historical Data

The historical data trend for Impedimed's Gross-Profit-to-Asset % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Impedimed Gross-Profit-to-Asset % Chart

Impedimed Annual Data
Trend Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24
Gross-Profit-to-Asset %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 14.43 20.07 18.91 15.23 15.10

Impedimed Semi-Annual Data
Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Gross-Profit-to-Asset % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 13.98 17.94 16.78 12.79 17.69

Competitive Comparison of Impedimed's Gross-Profit-to-Asset %

For the Medical Devices subindustry, Impedimed's Gross-Profit-to-Asset %, along with its competitors' market caps and Gross-Profit-to-Asset % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Impedimed's Gross-Profit-to-Asset % Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Impedimed's Gross-Profit-to-Asset % distribution charts can be found below:

* The bar in red indicates where Impedimed's Gross-Profit-to-Asset % falls into.



Impedimed Gross-Profit-to-Asset % Calculation

Impedimed's annualized Gross-Profit-to-Asset % for the fiscal year that ended in Jun. 2024 is calculated as:

Gross-Profit-to-Asset %=Gross Profit (A: Jun. 2024 )/( (Total Assets (A: Jun. 2023 )+Total Assets (A: Jun. 2024 ))/ count )
=8.739/( (68.736+46.986)/ 2 )
=8.739/57.861
=15.10 %

Impedimed's annualized Gross-Profit-to-Asset % for the quarter that ended in Jun. 2024 is calculated as:

Gross-Profit-to-Asset %=Gross Profit (Q: Jun. 2024 )/( (Total Assets (Q: Dec. 2023 )+Total Assets (Q: Jun. 2024 ))/ count )
=9.338/( (58.593+46.986)/ 2 )
=9.338/52.7895
=17.69 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Gross-Profit-to-Asset %, the Gross Profit of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Gross Profit data used here is two times the semi-annual (Jun. 2024) data. Gross-Profit-to-Asset % is displayed in the 30-year financial page.


Impedimed Gross-Profit-to-Asset % Related Terms

Thank you for viewing the detailed overview of Impedimed's Gross-Profit-to-Asset % provided by GuruFocus.com. Please click on the following links to see related term pages.


Impedimed Business Description

Traded in Other Exchanges
Address
50 Parker Court, Unit 1, Pinkenba, QLD, AUS, 4008
Impedimed Ltd, together with its subsidiaries, operates in the medical devices space. The company is based in Australia and operates globally, and it generates the majority of its revenue in North America. It is engaged in developing, manufacturing, and distributing noninvasive medical devices. The company offers products that are typically used to assess and monitor lymphedema and heart failure, as well as to measure the tissue composition and fluid status of the patients. The company also offers a cloud-based digital platform (branded as SOZO) to manage patient data. The company recognizes revenue from the stand-alone sale of Legacy Devices and Consumables, the Sale of SOZO Devices, and Software Subscription Services.

Impedimed Headlines

No Headlines